CHST5

Across TCGA pan-cancer cohorts, CHST5 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CHST5 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CHST5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHST5 expression acts as an unfavorable survival marker.

LUAD, KIRP, and LUSC are the cancer types where CHST5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.183	0.794	<.001	36	view →
KIRP	DFS	Median	All	0.037	0.920	<.001	24	view →
LUSC	DFS	Median	III,IV	0.132	0.664	.001	13	view →
ESCA	DFS	Median	II,III,IV	0.129	0.526	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	All	0.105	0.774	.002	6	view →
THCA	DFS	Median	All	0.652	0.944	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CHST5–LUAD (DFS)

Open the LUAD breakdown →